The lack of standardization in patient‐reported outcome measures (PROMs) has made measurement and comparison of quality of life (QoL) outcomes in research focused on obesity treatment challenging. This study reports on the results of the second and third global multidisciplinary Standardizing Quality of life measures in Obesity Treatment (S.Q.O.T.) consensus meetings, where a core set of PROMs to measure nine previously selected patient‐reported outcomes (PROs) in obesity treatment research was established. The S.Q.O.T. II online and S.Q.O.T. III face‐to‐face hybrid consensus meetings were held in October 2021 and May 2022. The meetings were led by an independent moderator specializing in PRO measurement. Nominal group techniques, Delphi exercises, and anonymous voting were used to select the most suitable PROMs by consensus. The meetings were attended by 28 and 27 participants, respectively, including a geographically diverse selection of people living with obesity (PLWO) and experts from various disciplines.Out of 24 PROs and 16 PROMs identified in the first S.Q.O.T. consensus meeting, the following nine PROs and three PROMs were selected via consensus: BODY‐Q (physical function, physical symptoms, psychological function, social function, eating behavior, and body image), IWQOL‐Lite (self‐esteem), and QOLOS (excess skin). No PROM was selected to measure stigma as existing PROMs deemed to be inadequate. A core set of PROMs to measure QoL in research focused on obesity treatment has been selected incorporating patients' and experts' opinions. This core set should serve as a minimum to use in obesity research studies and can be combined with clinical parameters.
| Original language | English |
|---|
| Article number | e13849 |
|---|
| Pages (from-to) | (In-Press) |
|---|
| Number of pages | 11 |
|---|
| Journal | Obesity Reviews |
|---|
| Volume | 26 |
|---|
| Issue number | 2 |
|---|
| Early online date | 17 Oct 2024 |
|---|
| DOIs | |
|---|
| Publication status | E-pub ahead of print - 17 Oct 2024 |
|---|
The S.Q.O.T. II meeting was funded by Medtronic, Johnson and Johnson, Philips Vital Health, Novo Nordisk, Castor, and Bart Torensma. The S.Q.O.T. III meeting was funded by Medtronic, Johnson and Johnson, Novo Nordisk, Goodlife, and Fitforme. The funders of the meeting were not involved in the selection of the PROs or PROMs. None of the members of the S.Q.O.T. organizing committee (PD, CV, VM, BW, IJ, and RL) and none of the participants of the consensus meetings received payment for their participation. Meeting spaces, audiovisual support, catering, travel expenses, and the hotel overnight for the meetings were supported by Johnson and Johnson (S.Q.O.T. II) and Medtronic, Johnson and Johnson, Novo Nordisk, Goodlife, and Fitforme (S.Q.O.T. III). Additionally, the moderator costs (CT) were supported by these sponsors. The sponsors played no role in the selection of participants of the meeting, in the selection of the domains and questionnaires included in this meeting, the voting rounds, or the writing of this paper, nor in any other research related activity. The S.Q.O.T. organizing committee (PD, CV, VM, BW, IJ, and RL) did not receive payment for their work for the S.Q.O.T. initiative.
- bariatric surgery
- obesity treatment
- patient-reported outcome
- quality of life
- Public Health, Environmental and Occupational Health
- Endocrinology, Diabetes and Metabolism